Magnetar Financial
CRVS icon

Magnetar Financial’s Corvus Pharmaceuticals CRVS Stock Holding History

Magnetar Financial’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-10,613
Closed -$128K – 754
2017
Q2 		$128K Buy
+10,613
New +$113K ﹤0.01% 760

Other funds holding CRVS

OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BVF Inc
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Magnetar Financial's CRVS Position: Q3 2017 in Review

Magnetar Financial sold out of Corvus Pharmaceuticals (CRVS) in Q3 2017, closing a stake of 10,613 shares — an estimated $128K sold.

Magnetar Financial first reported a position in CRVS in Q2 2017 and held it in 1 quarter. The position peaked at $128K in Q2 2017. 54 funds tracked by Wall St. Rank hold CRVS as of Q3 2017.

  • Magnetar Financial reported no remaining Corvus Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Magnetar Financial sold 10,613 Corvus Pharmaceuticals shares in Q3 2017, an estimated $128K.
  • Magnetar Financial first reported a position in Corvus Pharmaceuticals in Q2 2017 and held it in 1 quarter.
  • Magnetar Financial's Corvus Pharmaceuticals position peaked at $128K in Q2 2017.
  • 54 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q3 2017.

Based on Magnetar Financial's 13F filing for Q3 2017, filed 14 Nov 2017.